Secukinumab provides sustained improvements in clinical and imaging outcomes in patients with psoriatic arthritis and axial manifestations: results from the MAXIMISE trial

Secukinumab provides sustained improvements in clinical and imaging outcomes in patients with psoriatic arthritis and axial manifestations: results from the MAXIMISE trial

Bibliographic Details
Main Authors:	Baraliakos, X, Gossec, L, Pournara, E, Jeka, S, Blanco, R, D'Angelo, S, Schett, G, Schulz, B, Rissler, M, Whyms, D, Perella, C, Coates, LC
Format:	Conference item
Language:	English
Published:	Oxford University Press 2021

Similar Items

Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial
by: Baraliakos, X, et al.
Published: (2020)

Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial
by: Baraliakos, X, et al.
Published: (2022)

Magnetic resonance imaging characteristics in patients with psoriatic arthritis and axial manifestations from the MAXIMISE cohort
by: Baraliakos, X, et al.
Published: (2023)

Secukinumab demonstrates high and sustained efficacy in nail psoriasis: Post hoc analysis from phase 3 trials in patients with psoriatic arthritis
by: Reich, K, et al.
Published: (2022)

Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis
by: Pournara, E, et al.
Published: (2021)

Long term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease
by: Reich, K, et al.
Published: (2019)

Experience in using secukinumab in patients with axial psoriatic arthritis
by: E. E. Gubar, et al.
Published: (2020-11-01)

Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2–5 and MAXIMISE studies
by: Renaud Felten, et al.
Published: (2023-10-01)

Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement
by: G. Adami, et al.
Published: (2023-05-01)

Effect of secukinumab on the different GRAPPA-OMERACT core domains in psoriatic arthritis: a pooled analysis of 2049 patients
by: Orbai, A-M, et al.
Published: (2019)

How should we define disease and outcomes in axial psoriatic arthritis?
by: Coates, LC
Published: (2021)

Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
by: Coates, L, et al.
Published: (2019)

Axial spondyloarthritis and psoriatic arthritis: mostly overlapping or substantially different diseases?
by: Braun, J, et al.
Published: (2023)

Is axial psoriatic arthritis the same as ankylosing spondylitis with psoriasis: a debate
by: Coates, LC, et al.
Published: (2023)

Secukinumab treatment in psoriatic patients: Italian experiences
by: Luca Idolazzi
Published: (2018-11-01)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
by: Ogdie, A, et al.
Published: (2023)

Secukinumab in multi-failure psoriatic patients: the last hope?
by: M. Magnano, et al.
Published: (2018-08-01)

Treatment of psoriatic arthritis with secukinumab: a case series
by: Stefania Nicola, et al.
Published: (2018-11-01)

Treatment with secukinumab in multi-comorbid patients with psoriatic arthritis
by: Ombretta Viapiana, et al.
Published: (2018-12-01)

The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial
by: Strand, V, et al.
Published: (2022)

Interleukin 17A inhibitor secukinumab in the treatment of patients with psoriatic arthritis
by: N. A. Shostak, et al.
Published: (2022-10-01)

Improving the management of psoriatic arthritis and axial spondyloarthritis: Roundtable discussions with healthcare professionals and patients
by: Garrido-Cumbrera, M, et al.
Published: (2017)

Imaging in rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and osteoarthritis: An international viewpoint on the current knowledge and future research priorities
by: Xenofon Baraliakos, et al.
Published: (2019-01-01)

The updated GRAPPA and EULAR recommendations for the management of psoriatic arthritis: similarities and differences
by: Coates, L, et al.
Published: (2022)

Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis
by: Juan José Alegre-Sancho, et al.
Published: (2023-11-01)

LP-212 SLE overlap with psoriatic arthritis successfully treated with secukinumab
by: Athina Theodoridou
Published: (2023-07-01)

Cutaneous Vasculitis with Gut Involvement During Secukinumab Treatment for Psoriatic Arthritis
by: Clara Chelli, et al.
Published: (2020-03-01)

The effect of secukinumab treatment on hematological parameters in ankylosing spondylitis and psoriatic arthritis
by: Ahmet Karataş, et al.
Published: (2020-10-01)

Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies
by: Baraliakos, X, et al.
Published: (2023)

A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab
by: M. Galluzzo, et al.
Published: (2018-11-01)

Detectability of the peripheral and axial manifestations of psoriatic arthritis in patients with psoriasis in dermatological practice
by: M. N. Chamurlieva, et al.
Published: (2019-10-01)

Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
by: Paolo Gisondi, et al.
Published: (2022-04-01)

Secukinumab in the therapy of psoriasis and psoriatic arthritis: a safe choice in clinical practice
by: Andrea Chiricozzi
Published: (2018-12-01)

Description of the Clinical Case of Adalimumab and Secukinumab Therapy of a Patient with Psoriatic Arthritis
by: V. V. Didenko, et al.
Published: (2021-05-01)

Minimal disease activity among active psoriatic arthritis patients treated with secukinumab: 2‐year results from a multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled phase III study
by: Coates, L, et al.
Published: (2018)

Axial spondyloarthritis and psoriatic arthritis: mostly overlapping or substantially different diseases?
by: Juergen Braun, et al.
Published: (2023-04-01)

Outcome measures in psoriatic arthritis: where next?
by: Hackett, S, et al.
Published: (2022)

Psoriatic arthritis: prospects for the future
by: Hackett, S, et al.
Published: (2022)

Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum
by: Francisca Sivera, et al.
Published: (2023-05-01)

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis
by: Alexis Ogdie, et al.
Published: (2023-05-01)